{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Tris+Pharma%2C+Inc.",
    "query": {
      "sponsor": "Tris Pharma, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Tris+Pharma%2C+Inc.&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T13:58:28.666Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02083783",
      "title": "TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "TRI102",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 108,
      "start_date": "2014-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2020-08-26",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 5,
      "location_summary": "Newport Beach, California • Las Vegas, Nevada • Durham, North Carolina + 2 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02083783"
    },
    {
      "nct_id": "NCT04027361",
      "title": "Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Amphetamine Extended Release (ER) Tablet 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "18 Years to 25 Years"
      },
      "enrollment_count": 41,
      "start_date": "2019-10-01",
      "completion_date": "2021-10-15",
      "has_results": false,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04027361"
    },
    {
      "nct_id": "NCT01709214",
      "title": "Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "Cebranopadol (GRT6005) Low-Dose Range",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol (GRT6005) High-Dose Range",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone CR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 619,
      "start_date": "2012-12-04",
      "completion_date": "2014-04-04",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01709214"
    },
    {
      "nct_id": "NCT06423703",
      "title": "A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "Cebranopadol",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone IR",
          "type": "DRUG"
        },
        {
          "name": "Placebo Only",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 240,
      "start_date": "2024-07-18",
      "completion_date": "2025-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 10,
      "location_summary": "Sheffield, Alabama • Little Rock, Arkansas • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06423703"
    },
    {
      "nct_id": "NCT06545097",
      "title": "A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "Cebranopadol 400 ug",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol 200 ug",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 279,
      "start_date": "2024-09-03",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Miami, Florida • Bellaire, Texas + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06545097"
    },
    {
      "nct_id": "NCT03958123",
      "title": "Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prolonged QTc Interval",
        "Pharmacokinetic"
      ],
      "interventions": [
        {
          "name": "100 μg cebranopadol",
          "type": "DRUG"
        },
        {
          "name": "200 μg cebranopadol",
          "type": "DRUG"
        },
        {
          "name": "400 μg cebranopadol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to cebranopadol encapsulated tablets",
          "type": "DRUG"
        },
        {
          "name": "400 mg Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to moxifloxacin encapsulated tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 171,
      "start_date": "2013-07-10",
      "completion_date": "2013-11-27",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03958123"
    },
    {
      "nct_id": "NCT00872885",
      "title": "Bunionectomy Trial With GRT6005",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post Operative Pain"
      ],
      "interventions": [
        {
          "name": "GRT6005",
          "type": "DRUG"
        },
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 258,
      "start_date": "2009-03",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00872885"
    },
    {
      "nct_id": "NCT07650643",
      "title": "EEG Biomarkers for ADHD Stimulant Treatment",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "methylphenidate HCl",
          "type": "DRUG"
        },
        {
          "name": "Mixed amphetamine salts extended release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "7 Years to 11 Years"
      },
      "enrollment_count": 220,
      "start_date": "2026-09-15",
      "completion_date": "2031-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 1,
      "location_summary": "Brookline, Massachusetts",
      "locations": [
        {
          "city": "Brookline",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07650643"
    },
    {
      "nct_id": "NCT03610464",
      "title": "Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Amphetamine Extended Release Suspension [Dyanavel]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "4 Years to 5 Years"
      },
      "enrollment_count": 5,
      "start_date": "2018-05-07",
      "completion_date": "2018-05-23",
      "has_results": true,
      "last_update_posted_date": "2019-06-25",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 1,
      "location_summary": "Maitland, Florida",
      "locations": [
        {
          "city": "Maitland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03610464"
    },
    {
      "nct_id": "NCT06453265",
      "title": "A Study to Assess the Abuse Potential of Intranasal Cebranopadol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Abuse, Drug"
      ],
      "interventions": [
        {
          "name": "Cebranopadol- 600 ug",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol- 800ug",
          "type": "DRUG"
        },
        {
          "name": "Cebranopadol- 1000ug",
          "type": "DRUG"
        },
        {
          "name": "Treatment A:",
          "type": "DRUG"
        },
        {
          "name": "Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Qualification",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tris Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2024-06-28",
      "completion_date": "2024-11-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-09T13:58:28.666Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06453265"
    }
  ]
}